Skip to main content

Table 4 Univariate and multivariate analyses for PFS of ovarian cancer

From: Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients

Univariate analysis
Variable n (%) Median (months) p value
Age:    
 <70 118 (94.4 %) 10.4 0.51
 ≥70 7 (5.6 %) 16.0  
Performance status WHO:    
 ▪ 0 19 (15.2 %) 14.7 0.06
 ▪ Other 106 (84.8) 21.4  
FIGO stage:    
 ▪ Early (I,II) 24 (19.2 %) NR < 0.001
 ▪ Advanced (III, IV) 101 (80.8 %) 13.4  
Chemotherapy regimen:    
 ▪ With paclitaxel 113 (90.4 %) 16.8 0.032
 ▪ Without paclitaxel 12 (9.6 %) 10.3  
Chemotherapy regimen:    
 ▪ With cisplatin 55 (44.0 %) 23.0 0.24
 ▪ With carboplatin 70 (56.0 %) 13.5  
Type of histology:    
 ▪ Serous 68 (54.4 %) 13.2 < 0.001
 ▪ Other 57 (45.6 %) 34.8  
Grading:    
 ▪ 1 and 2 45 (36.0 %) 16.0 0.40
 ▪ 3 and unspecified 80 (64.0 %) 14.6  
Primary surgery:    
 ▪ Optimal (<1 cm) 77 (61.6 %) 24.7 < 0.001
 ▪ Suboptimal (>1 cm) 48 (38.4 %) 11.0  
BRCA1 status:    
 ▪ Wild type 108 (86.4 %) 14.6 0.58
 ▪ Germline mutation 17 (13.6 %) 21.5  
Multivariate analysis
Variable HR (95 % CI) p value
FIGO stage:
 ▪ Early (I,II) 0.21 (0.071 – 0.634) 0.006
 ▪ Advanced (III, IV)
Chemotherapy regimen:
 ▪ With paclitaxel 0.46 (0.242 – 1.020) 0.034
 ▪ Without paclitaxel
Type of histology:
 ▪ Serous 0.55 (0.318 – 0.916) 0.027
 ▪ Other
Primary surgery:
 ▪ Optimal (<1 cm) 0.54 (0.308 – 0.804) 0.011
 ▪ Suboptimal (>1 cm)
BRCA1 status: NG NS
 ▪ Wild type
 ▪ Germline mutation   
  1. NG not given, NR not reached, NS statistically not significant